home · filing · 0000950170-23-031366
8-K filed July 3, 2023, 7:59 PM ET
ticker RNLXY
CIK 0001811115
leadership
confidence high
sentiment neutral
materiality 0.35
Renalytix appoints Catherine Coste to Board of Directors as Audit Chair
Renalytix plc
Catherine Coste, former Deloitte senior partner, appointed to board effective June 30, 2023.
She will serve as Non-Executive Chair of Audit Committee and member of Remuneration Committee.
Compensation: $40k/year director fee, plus $20k for Audit Chair, $7k for Remuneration Committee.
Coste has 32 years finance experience, CPA, and serves on two other public company boards.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Catherine Coste
Director
Effective 2023-06-30
Filed July 3, 2023, 7:59 PM ET
On June 30, 2023, Catherine Coste was appointed to the Board of Directors (the “Board”) of Renalytix plc (the “Company”).
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Catherine Coste was appointed as Director at Renalytix plc.
Action appointed
Role Director
Exact text from the filing
On June 30, 2023, Catherine Coste was appointed to the Board of Directors (the “Board”) of Renalytix plc (the “Company”).
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-23-031366
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.